RhumbLine Advisers
BDRX

RhumbLine Advisers’s Biodexa Pharmaceuticals BDRX Stock Holding History

RhumbLine Advisers’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8 Sell
3
-1
-25% -$3 ﹤0.01% 4124
2026
Q1 		$11 Sell
4
-1
-20% -$7 ﹤0.01% 4082
2025
Q4 		$54 Buy
5
+4
+400% +$114 ﹤0.01% 4101
2025
Q3 		$32 Hold
1
– – ﹤0.01% 4100
2025
Q2 		$59 Sell
1
-5
-83% -$319 ﹤0.01% 4113
2025
Q1 		$414 Buy
6
+3
+100% +$525 ﹤0.01% 4066
2024
Q4 		$628 Sell
3
-2
-40% -$522 ﹤0.01% 4094
2024
Q3 		$1.7K Buy
5
+3
+150% +$2.3K ﹤0.01% 4067
2024
Q2 		$2.42K Buy
+2
New +$2.62K ﹤0.01% 4168
2024
Q1 		– Hold
0
– – – 4162
2023
Q4 		– Hold
0
– – – 4130
2023
Q3 		– Hold
0
– – – 4174
2023
Q2 		– Hold
0
– – – 4362

Other funds holding BDRX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

RhumbLine Advisers's BDRX Position: Q2 2026 in Review

RhumbLine Advisers reduced its Biodexa Pharmaceuticals (BDRX) stake by 25% in Q2 2026, selling an estimated $3 and leaving 3 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #4124.

RhumbLine Advisers first reported a position in BDRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.42K in Q2 2024. 7 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • RhumbLine Advisers held 3 shares of Biodexa Pharmaceuticals worth $8 as of Q2 2026.
  • RhumbLine Advisers sold 1 Biodexa Pharmaceuticals share in Q2 2026, an estimated $3.
  • Biodexa Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #4124 holding.
  • RhumbLine Advisers first reported a position in Biodexa Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • RhumbLine Advisers's Biodexa Pharmaceuticals position peaked at $2.42K in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.